Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New gene marker may identify need for intense AML therapy

15.11.2005


Researchers here have discovered a new marker that might identify a serious form of acute myeloid leukemia (AML) in people who lack the signs that normally alert doctors that the patient needs intense therapy.



The study was led by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. It focused on AML patients whose cancer cells show none of the chromosome alterations that help doctors determine the probable prognosis and the best potential treatment for many people with acute leukemia.

Specifically, the study examined the activity of a gene known as ETS-Related Gene (ERG) in AML cells from these patients.


The findings, published online in the Journal of Clinical Oncology, suggest that when AML cells show high ERG activity, it signals an aggressive form of cancer that requires intense therapy, such as a stem-cell transplant from a matched donor.

Importantly, the study also showed that effects of ERG activity on disease relapse and long-term survival are influenced by the activity levels of other genes.

Last, the study suggests that ERG plays an important role in AML development and could provide a new target for future AML therapy.

The findings come from a Cancer and Leukemia Group B (CALGB) study led by Clara D. Bloomfield, professor of internal medicine, the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU Cancer Program.

“This is another of only a few predictive molecular markers for adults with AML who have normal cytogenetics,” says Bloomfield, who led the research that identified the first molecular marker for AML in this group of patients. Normal cytogenetics refers to cells with normal-looking chromosomes.

“If confirmed, our findings should improve survival in these patients and spare those who now receive more intense therapy but don’t need it.”

About 55 percent of AML patients have cancer cells showing chromosome alterations at the time of diagnosis. Doctors rely on these alterations to help determine the best therapy for these patients and the likelihood of remission and cure.

But the cancer cells in about 45 percent of AML patients have normal-looking chromosomes, giving doctors few clues for choosing therapy. Overall about 40 percent of these patients are alive after five years following intensive therapy.

“This means that 60 percent of patients relapse,” Bloomfield says, “and that probably happens because those who relapse have unidentified gene mutations and molecular changes that affect survival and their response to treatment.

“Some examples of these mutations and molecular changes have already been identified. ERG is probably another, and I have no doubt that more will be found.”

The present study tested whether activity levels of ERG are related to remission and survival rates in AML patients with normal cytogenetics.

(Levels of gene activity, or more correctly, gene expression, refers to whether a gene is highly, moderately or not engaged in the production of a protein. Gene-expression levels are determined by measuring the number of RNA copies of the gene that are present in cells. A high number of RNA copies indicates a high level of gene activity; a low number indicates low gene activity.)

The study examined samples of cancer cells from 84 AML patients under age 60 years who had normal cytogenetics. The samples were analyzed for the activity levels of ERG and other genes known to influence treatment response in these patients.

The 84 samples were then divided into four groups according to ERG activity. The group with high ERG activity was compared with the other three groups combined in terms of the patients’ relapse and survival rates.

In general, the group with high ERG did extremely poorly compared with the other groups when consider by itself and in combination with other genes.

When the researchers looked at the likelihood of relapse and the influence of high ERG by itself, they found that 81 percent of high ERG patients relapsed after five years versus 33 percent of patients in the other groups.

However, when the risk of relapse was examined in combination with a second gene known as MLL PTD, patients with high ERG were four times more likely to relapse than the patients with low ERG..

When the researchers considered survival and the influence of ERG alone, they found that the group with high ERG lived an average of 1.2 years following treatment, while the other three groups had not yet reached their average survival when the study ended.

When the researchers then examined the impact of ERG in combination with other factors on survival, they found that the patients who did best had low ERG and low activity of a gene known as BAALC. Seventy percent of these patients were alive after five years.

“This study is important because we have found another gene (ERG) that seems to have a major influence in this large subset of AML patients,” Bloomfield says, “and we’ve identified other genes that alter ERG’s effects on relapse and survival.”

Overall, the evidence strongly indicates that ERG may play a key role in leukemia development. Therefore, a drug that is designed to reduce ERG activity, perhaps in combination with chemotherapy or other targeted therapy, “might prevent these patients from relapsing,” Bloomfield says, “and that would be quite a success.”

Other OSU researchers involved in this study were Guido Marcucci, Claudia D. Baldus, Amy S. Ruppert, Krzysztof Mrozek, Susan P. Whitman, Colin G. Edwards, Danilo Perrotti, Michael A. Caligiuri and Albert de la Chapelle.

Funding from the National Cancer Institute and The Coleman Leukemia Research Foundation supported this research.

Darrell E. Ward | EurekAlert!
Further information:
http://www.osumc.edu

More articles from Life Sciences:

nachricht New photocatalyst speeds up the conversion of carbon dioxide into chemical resources
29.05.2017 | DGIST (Daegu Gyeongbuk Institute of Science and Technology)

nachricht Copper hydroxide nanoparticles provide protection against toxic oxygen radicals in cigarette smoke
29.05.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>